138 related articles for article (PubMed ID: 3142080)
1. A fibrin specific monoclonal antibody which interferes with the fibrinolytic effect of tissue plasminogen activator.
Gargan PE; Ploplis VA; Scheu JD
Thromb Haemost; 1988 Jun; 59(3):426-31. PubMed ID: 3142080
[TBL] [Abstract][Full Text] [Related]
2. [Functional characterization of a monoclonal antibody which interferes with the binding of t-PA to fibrin].
Orbe J; Montes R; Chordá C; Páramo JA; Rocha E
Sangre (Barc); 1994 Aug; 39(4):261-6. PubMed ID: 7985055
[TBL] [Abstract][Full Text] [Related]
3. Production and characterization of monoclonal antibodies against tissue-type plasminogen activator.
Ding H; Wang JY; Song HY
Chin J Biotechnol; 1990; 6(3):223-7. PubMed ID: 2129498
[TBL] [Abstract][Full Text] [Related]
4. Bispecific monoclonal antibodies produced by somatic cell fusion increase the potency of tissue plasminogen activator.
Branscomb EE; Runge MS; Savard CE; Adams KM; Matsueda GR; Haber E
Thromb Haemost; 1990 Oct; 64(2):260-6. PubMed ID: 2125375
[TBL] [Abstract][Full Text] [Related]
5. [Use of monoclonal antibodies in the diagnosis of fibrinolysis].
Wojta J; Korninger C; Kirchheimer J; Hattey E; Turcu L; Binder BR
Wien Klin Wochenschr; 1985 Mar; 97(5):244-8. PubMed ID: 4039506
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of fibrinolysis by bispecific monoclonal antibodies reactive to fibrin and plasminogen activators.
Kurokawa T; Iwasa S; Kakinuma A
Thromb Res Suppl; 1990; 10():83-9. PubMed ID: 2107601
[TBL] [Abstract][Full Text] [Related]
7. The monoclonal antibody that recognizes an epitope in the C-terminal region of the fibrinogen alpha-chain reacts with soluble fibrin and fibrin monomer generated by thrombin but not with those formed as plasmin degradation products.
Suzuki A; Ebinuma H; Matsuo M; Miyazaki O; Yago H
Thromb Res; 2007; 121(3):377-85. PubMed ID: 17561232
[TBL] [Abstract][Full Text] [Related]
8. Characterization of monoclonal antibodies to human tissue-type plasminogen activator: catalytic inhibition and one-two chain discriminatory reactivities.
Stigbrand T; Frängsmyr L; Bergsdorf N; Wallen P
Thromb Haemost; 1989 Sep; 62(2):742-7. PubMed ID: 2479112
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies towards the fast inhibitor of tissue plasminogen activator from human plasma and serum.
Urdén G; Johansson U; Chmielewska J; Brandt J; Wiman B
Thromb Haemost; 1986 Jun; 55(3):383-7. PubMed ID: 3092395
[TBL] [Abstract][Full Text] [Related]
10. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion.
Holvoet P; Lijnen HR; Collen D
Blood; 1986 May; 67(5):1482-7. PubMed ID: 3083892
[TBL] [Abstract][Full Text] [Related]
11. Characterization of two monoclonal antibodies against human tissue-type plasminogen activator.
Schleef RR; Sinha M; Loskutoff DJ
Thromb Haemost; 1985 Apr; 53(2):170-5. PubMed ID: 4040658
[TBL] [Abstract][Full Text] [Related]
12. Characterisation of epitopes on human tissue plasminogen activator recognised by a group of monoclonal antibodies.
MacGregor IR; Micklem LR; James K; Pepper DS
Thromb Haemost; 1985 Feb; 53(1):45-50. PubMed ID: 2581330
[TBL] [Abstract][Full Text] [Related]
13. Selection of monoclonal antibodies that bind and inhibit tissue-type plasminogen activator.
Ball EL; Dunlop K; Matsueda GR
Hybridoma; 1993 Jun; 12(3):317-26. PubMed ID: 8359825
[TBL] [Abstract][Full Text] [Related]
14. Characterization of monoclonal antibodies against human tissue plasminogen activator (tPA): quantitation of free tPA in human cell cultures by an ELISA.
Kurokawa T; Toyoda Y; Iwasa S
J Biochem; 1991 Feb; 109(2):217-22. PubMed ID: 1713912
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy.
Collen D
J Cell Biochem; 1987 Feb; 33(2):77-86. PubMed ID: 3553213
[TBL] [Abstract][Full Text] [Related]
16. Binding of a new monoclonal antibody against N-terminal heptapeptide of fibrin alpha-chain to fibrin polymerization site 'A': effects of fibrinogen and fibrinogen derivatives, and pretreatment of samples with NaSCN.
Dempfle CE; Dollman M; Lill H; Puzzovio D; Dessauer A; Heene DL
Blood Coagul Fibrinolysis; 1993 Feb; 4(1):79-86. PubMed ID: 8457657
[TBL] [Abstract][Full Text] [Related]
17. Antibody-enhanced thrombolysis: capture of tissue plasminogen activator by a bispecific antibody and direct targeting by an antifibrin-tissue plasminogen activator conjugate in vivo.
Runge MS; Bode C; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1987; 100():250-5. PubMed ID: 3137708
[No Abstract] [Full Text] [Related]
18. Beta2-glycoprotein I, anti-beta2-glycoprotein I, and fibrinolysis.
Yasuda S; Atsumi T; Ieko M; Koike T
Thromb Res; 2004; 114(5-6):461-5. PubMed ID: 15507279
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies to human 54,000 molecular weight plasminogen activator inhibitor from fibrosarcoma cells--inhibitor neutralization and one-step affinity purification.
Nielsen LS; Andreasen PA; Grøndahl-Hansen J; Huang JY; Kristensen P; Danø K
Thromb Haemost; 1986 Apr; 55(2):206-12. PubMed ID: 3520936
[TBL] [Abstract][Full Text] [Related]
20. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
